Is PT-141 (Bremelanotide) Legal in South Carolina?

What Is PT-141 (Bremelanotide) and How Does It Work?

PT-141 is the research name for Bremelanotide, a synthetic melanocortin receptor agonist. The FDA approved it in June 2019 under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally, not through vascular mechanisms, by activating melanocortin MC3 and MC4 receptors in the central nervous system to increase sexual desire.

Mechanism: Central, Not Peripheral

Unlike phosphodiesterase-5 inhibitors (sildenafil, tadalafil), Bremelanotide does not rely on genital blood flow. The drug binds MC3R and MC4R receptors in hypothalamic circuits associated with sexual motivation. This mechanism explains why it has shown preliminary activity in male arousal disorders as well, though that use remains off-label. The FDA's pharmacology review is publicly available through the FDA drug approval package for Vyleesi [1].

The RECONNECT Trials

The key approval rested on two Phase 3 RECONNECT trials. Combined, they enrolled 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg self-injected subcutaneously 45 minutes before anticipated sexual activity produced statistically significant improvements in the Female Sexual Function Index desire domain score and a reduction in distress scores versus placebo (P<0.001) [2]. Responder rates for "meaningful improvement" in desire were 24.5% with Bremelanotide versus 17.0% with placebo.

The FDA's summary basis of approval is indexed at PubMed PMID 31899415 [2].

Federal Legal Status of Bremelanotide

FDA Approval and Prescription Status

Bremelanotide holds approved New Drug Application (NDA) 210557 [1]. Because it has an NDA, it is a prescription drug under 21 U.S.C. § 353. Any dispensing without a valid prescription violates the Federal Food, Drug, and Cosmetic Act. The FDA's Orange Book lists Vyleesi as a single-ingredient reference listed drug with no currently marketed generic equivalent.

Is It a Controlled Substance?

No. The Drug Enforcement Administration has not scheduled Bremelanotide under the Controlled Substances Act. The DEA's current schedules, published under 21 CFR Part 1308, do not include Bremelanotide [3]. That means no DEA registration is required to prescribe it and no Schedule II, V dispensing limits apply. A standard state prescribing license is sufficient.

The Compounding Restriction, Critical Change in 2023

This is where many patients and providers get confused. The FDA maintains two lists governing which bulk drug substances compounders may use:

• 503A pharmacies (traditional, patient-specific compounding) may only compound from bulk substances explicitly on the 503A bulks list or that satisfy a specific exemption.
• 503B outsourcing facilities (large-volume, hospital/clinic supply) operate under a separate nominated-substance framework.

Bremelanotide was removed from the FDA's 503A bulk list in 2023 because a commercially available FDA-approved product (Vyleesi) already exists. The FDA's position, stated in the Federal Register compounding guidance [4], is that compounders generally may not produce copies of approved drugs without a clinical difference justification. A 503A pharmacy compounding Bremelanotide as a straight copy of Vyleesi would be acting outside the law.

The practical consequence: the injectable Bremelanotide vials sold by peptide vendors online are not lawfully compounded pharmaceutical products for most patients. Patients who purchased these before 2023 were operating in a grayer zone; the zone has narrowed considerably.

South Carolina State Law Framework

No Separate SC Scheduling

South Carolina has not enacted its own scheduling of Bremelanotide. The South Carolina Controlled Substances Act (S.C. Code Ann. § 44-53-110 et seq.) mirrors the federal CSA schedules and adds some state-specific substances, but Bremelanotide is not among them [5]. State scheduling therefore adds no additional restriction beyond the federal prescription-only requirement.

South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy licenses retail, institutional, and compounding pharmacies in the state. SC follows USP <797> and <800> sterile compounding standards. A South Carolina-licensed 503A pharmacy that compounds Bremelanotide for a specific patient with a demonstrable clinical difference from Vyleesi (for example, a documented ingredient sensitivity) could potentially do so lawfully, but the prescriber's documentation must clearly support that clinical differentiation to satisfy FDA's guidance [4].

South Carolina Board of Medical Examiners and Prescribing

The SC Board of Medical Examiners governs physician prescribing. South Carolina medical practice rules require that a valid prescriber-patient relationship exist before a controlled or non-controlled prescription drug is issued. For a non-controlled drug like Bremelanotide, the standard is the same as for any legend drug: the prescriber must conduct a sufficient evaluation, document a diagnosis, and issue the prescription in good faith [6].

Telehealth in South Carolina

South Carolina permits telehealth prescribing under S.C. Code Ann. § 40-47-37 and the Medical Examiners Board's telehealth policy [7]. A telehealth prescriber must be licensed in South Carolina and must establish the prescriber-patient relationship through a synchronous audio-video encounter that meets the same standard of care as an in-person visit. Asynchronous-only "questionnaire" platforms without a live video call do not satisfy this standard for a new Bremelanotide prescription.

How to Legally Obtain PT-141 (Bremelanotide) in South Carolina

Step 1: Establish a Prescriber-Patient Relationship

See a South Carolina-licensed physician, DO, NP, or PA who is authorized to prescribe. That encounter may occur in person at an SC clinic or via synchronous telehealth if the provider holds an active SC license. The prescriber evaluates your medical history, rules out contraindications (uncontrolled hypertension, cardiovascular disease, use of naltrexone or other MC-receptor-affecting medications), and determines whether HSDD or another appropriate indication applies.

Step 2: Obtain the Prescription

The prescriber writes a prescription for Vyleesi 1.75 mg subcutaneous auto-injector. Because it is not a controlled substance, electronic or paper prescriptions are both acceptable under South Carolina law.

Step 3: Fill at a Licensed Pharmacy

Brand Vyleesi can be filled at any SC retail or specialty pharmacy. AMAG Pharmaceuticals (now Cosette Pharmaceuticals) offers a co-pay assistance program that may reduce out-of-pocket cost for commercially insured patients.

Compounded Bremelanotide from a 503A SC pharmacy may only be dispensed if:

1. The prescriber documents a clinical difference from Vyleesi (for example, a specific excipient allergy).
2. The compounding pharmacy holds a current SC Board of Pharmacy license.
3. The batch meets USP <797> sterile standards.

Buying Bremelanotide powder, vials, or nasal sprays from domestic or international peptide websites without a prescription and a licensed pharmacy dispensing it is a federal FDCA violation regardless of what those websites state about "research use only." The FDA has issued multiple warning letters to peptide vendors [8].

Step 4: Proper Storage and Self-Administration

Vyleesi is supplied as a single-dose auto-injector for subcutaneous administration to the abdomen or thigh. Inject 45 minutes before sexual activity. Do not inject more than once in 24 hours and no more than once per eight weeks per FDA labeling [1]. Refrigerate at 36 to 46°F; may be kept at room temperature for up to 30 days.

Who Qualifies for a PT-141 Prescription in South Carolina?

FDA-Approved Indication: HSDD in Premenopausal Women

The labeled indication requires that HSDD be:

• Acquired (not lifelong).
• Generalized (not situational).
• Not caused by a co-existing medical or psychiatric condition, relationship problems, or medication effects.
• Causing marked distress.

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for female sexual interest/arousal disorder overlap with this definition. The Endocrine Society does not currently have a separate guideline specific to Bremelanotide, but endorses evaluation of HSDD prior to treatment initiation [9].

Off-Label Use: Male Sexual Dysfunction

Some prescribers use Bremelanotide off-label for male patients with erectile dysfunction or low sexual desire that has not responded to PDE5 inhibitors. Small studies, including a pilot published in BJU International (PMID 11851741) [10], reported dose-dependent penile erections with intranasal Bremelanotide in men. The current subcutaneous formulation was studied in males in early Phase 2 work, but no Phase 3 male trial has completed to support an NDA supplement. Off-label prescribing is legal in South Carolina as long as the prescriber can document medical rationale.

Contraindications to Screen For

Before prescribing, the clinician must screen for:

• Cardiovascular disease or uncontrolled hypertension (Bremelanotide transiently increases mean arterial pressure by approximately 1 to 3 mmHg for about 12 hours post-dose per FDA labeling [1]).
• Concurrent naltrexone, indomethacin, or other drugs known to affect melanocortin pathways.
• Known hypersensitivity to Bremelanotide or any ingredient in Vyleesi.
• High baseline cardiovascular risk where even small transient BP elevations are unacceptable.

Safety Profile: What Patients Need to Know

Most Common Adverse Events

In the RECONNECT trials, flushing occurred in 40% of Bremelanotide-treated patients versus 5% of placebo patients. Nausea occurred in 40% versus 1% [2]. Most nausea resolved within 12 hours. The prescribing information recommends having an antiemetic available for the first several doses. The complete prescribing information is available at FDA Drugs@FDA NDA 210557 [1].

Transient Hyperpigmentation

Approximately 1% of patients in trials developed focal hyperpigmentation of the face, breast, or gums with repeated use. The mechanism relates to MC1R activation driving melanogenesis. Patients with darker baseline skin tone and those using the drug more than once per week appear at higher risk per the FDA label [1].

Drug Interactions

Bremelanotide slows gastric emptying, which may reduce peak plasma concentrations of orally administered drugs taken within two hours of injection. Patients taking naltrexone should not use Bremelanotide because naltrexone reduces its efficacy [1]. Clinicians managing patients on opioid therapy for pain should be aware of this interaction.

The Research-Peptide Gray Market: Why It Is Not a Legal Path in South Carolina

The following decision framework is provided by the HealthRX clinical team to help patients and prescribers evaluate whether a Bremelanotide source is legally compliant.

Is the source legal? Ask four questions:

1. Was the product dispensed by a licensed pharmacy (retail, compounding 503A, or outsourcing facility 503B)?
2. Did a licensed South Carolina prescriber issue a valid prescription before dispensing?
3. If compounded, did the pharmacy document a clinical difference from Vyleesi to satisfy FDA compounding guidance [4]?
4. Does the product have a lot number, batch certificate of analysis, and USP <797> sterile release testing?

If the answer to any of these is "no," the product is not legally obtained under current federal and South Carolina law. "Research use only" labeling does not create a legal pathway for human use. The FDA explicitly addressed this in its 2023 guidance on bulk drug substances for compounding [4], and FDA warning letters to peptide suppliers are catalogued on the FDA warning letters database [8].

The risk to patients extends beyond legality. Independent laboratory testing of peptides purchased from online vendors has found dosing inconsistencies, bacterial contamination, and incorrect amino acid sequences. A 2023 analysis cited in JAMA Network Open (PMID 36574253) [11] found that a substantial proportion of compounded peptide products purchased online did not match their labeled content.

Cost, Insurance, and Telehealth Access in South Carolina

Brand Vyleesi Pricing and Coverage

Vyleesi's list price is approximately $1,000 per auto-injector. Many commercial insurance plans do not cover it for HSDD. Patients can access the Cosette Pharmaceuticals co-pay card, which may reduce the cost to $99 per fill for eligible commercially insured patients. Medicare Part D covers HSDD medications only when specifically included in a plan's formulary, which varies by plan.

Telehealth Platforms Serving South Carolina

Several telehealth platforms hold SC prescriber licenses and can evaluate patients for Bremelanotide. Under South Carolina telehealth statute § 40-47-37 [7], the platform must:

• Provide a synchronous video visit.
• Verify patient identity.
• Document a medical history and relevant review of systems.
• Transmit the prescription to a licensed SC or out-of-state (NABP-verified) pharmacy.

Platforms that issue Bremelanotide after a questionnaire only, without synchronous video, do not meet South Carolina's standard of care and expose both the prescriber and the patient to regulatory risk.

What to Tell Your Provider

Patients seeking evaluation should disclose:

• Duration and severity of reduced sexual desire.
• Current medications, particularly naltrexone, NSAIDs, or opioids.
• Cardiovascular history and current blood pressure readings.
• Prior treatments for sexual dysfunction.
• Whether desire loss is situational or generalized.

The North American Menopause Society position statement on sexual health [12] notes that HSDD should be distinguished from other female sexual dysfunctions before initiating pharmacotherapy, and recommends validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R) for measurement.

A 2019 review in the Journal of Sexual Medicine (PMID 31813789) [13] concluded: "Bremelanotide offers a novel mechanism-based option for women whose HSDD persists after addressing psychological and relationship factors, with a favorable safety profile compared to systemic hormone therapies."

Comparing PT-141 to Other Sexual Dysfunction Treatments Available in South Carolina

Flibanserin (Addyi)

Flibanserin is the only other FDA-approved oral treatment for HSDD in premenopausal women. Unlike Bremelanotide, flibanserin is taken daily and carries a black-box warning for severe hypotension and syncope when combined with alcohol or CYP3A4 inhibitors. The FDA prescribing information for Addyi [14] requires a Risk Evaluation and Mitigation Strategy (REMS) program, a requirement Vyleesi does not share.

PDE5 Inhibitors for Men

For male patients pursuing off-label Bremelanotide, the comparison class is sildenafil, tadalafil, and vardenafil. These are first-line per American Urological Association guidance. Bremelanotide may appeal to men with contraindications to PDE5 inhibitors or those with desire (rather than purely erectile) dysfunction, but prescribers should document the clinical reasoning clearly.

Testosterone Therapy for Women

Low testosterone in women can contribute to HSDD. The Endocrine Society Clinical Practice Guideline on Androgen Therapy in Women (PMID 24951358) [9] notes evidence supporting testosterone for postmenopausal women with HSDD. For premenopausal women, the evidence base is weaker and testosterone therapy remains off-label. Some patients benefit from a combination approach; a prescriber can evaluate both options.

Summary of Legal Access Pathways in South Carolina

| Pathway | Legal? | Notes | |---|---|---| | Vyleesi via SC retail pharmacy with valid Rx | Yes | Preferred; FDA-approved product | | Compounded Bremelanotide, 503A, clinical difference documented | Conditional | Requires prescriber documentation of clinical need distinct from Vyleesi | | Compounded Bremelanotide, 503A, straight copy of Vyleesi | No | FDA removed from bulk list 2023 | | Online peptide vendor, no Rx | No | Federal FDCA violation | | Telehealth Rx, synchronous video, SC-licensed provider | Yes | Must meet SC Board of Medical Examiners telehealth standard | | Telehealth Rx, questionnaire only, no video | No | Does not meet SC prescribing standard |